Foghorn Therapeutics (FHTX) Earnings Date & Reports

Key Takeaways

• Foghorn Therapeutics (FHTX) is expected to report second-quarter 2026 results in early August, with the estimated earnings date falling around August 4–6, before the market opens.
• Consensus estimates point to a net loss of approximately $0.25 per share, an improvement from the $0.28 loss reported in Q2 2025, alongside collaboration revenue of roughly $7.05 million.
• Investor attention will center heavily on any updates regarding the FHD-909 Phase 1 dose-expansion decision, a key catalyst expected from its 50/50 partnership with Eli Lilly.
• The company enters the quarter with a strong balance sheet of $183.6 million in cash and equivalents as of March 31, 2026, providing runway into the first half of 2028.
• FHTX shares have experienced elevated volatility, reflecting the binary nature of upcoming clinical readouts and broader biotech sector sentiment.

Earnings Context and Why It Matters

Foghorn Therapeutics remains a clinical-stage biotechnology company with no product revenue, meaning its quarterly financial results are primarily a reflection of collaboration income and operating expense management. For a pre-revenue biotech like Foghorn, earnings reports serve less as a scorecard of commercial performance and more as a checkpoint on cash burn, pipeline progress, and strategic direction. This particular quarter carries heightened significance because it coincides with the anticipated FHD-909 dose-expansion decision with Eli Lilly, which CEO Adrian Gottschalk has guided for summer 2026. With a market capitalization of roughly $305 million and a beta of 2.86 — indicating nearly three times the volatility of the broader market — FHTX shares are poised for potential sharp moves based on any pipeline-related disclosures during or around the earnings release.

Earnings Expectations

Analyst consensus for Foghorn's second quarter of 2026 points to a net loss around $0.25 per share, with estimates ranging from a loss of $0.17 to a loss of $0.30 depending on the source. This would represent a year-over-year improvement from the $0.28 per-share loss recorded in the second quarter of 2025. On the top line, collaboration revenue is expected to land near $7.05 million, slightly below the $7.56 million reported in the same quarter last year, reflecting the variable timing of work performed under the Lilly collaboration agreement. In the most recent first quarter of 2026, Foghorn reported EPS of -$0.29 on revenue of $3.27 million, notably missing the consensus revenue estimate of $7.94 million — a reminder that collaboration revenue can fluctuate meaningfully from quarter to quarter. Research and development (R&D) expenses are expected to remain the primary driver of operating costs, with Q1 2026 R&D spend coming in at $18.3 million, down from $21.6 million a year earlier due to lower Lilly-partnered program costs and reduced spending on the discontinued FHD-286 program.

AI Screener

For investors tracking earnings season across the biotechnology sector and beyond, Tickeron's AI Screener provides a powerful AI-driven platform designed to help traders and investors filter thousands of stocks and exchange-traded funds (ETFs) using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and proprietary AI-generated signals. The tool enables users to efficiently identify trade ideas, breakout candidates, trending stocks, and emerging opportunities without manually sorting through data. In a market environment where timely and targeted filtering can make the difference between catching or missing a catalyst-driven move, the AI Screener offers a streamlined solution worth exploring.

Market Reaction and Investor Sentiment

Heading into the Q2 2026 report, investor sentiment around FHTX appears cautiously optimistic but deeply tied to pipeline catalysts rather than quarterly financial metrics. The stock closed at $5.20 on July 27, 2026, near the midpoint of its 52-week range of $3.27 to $6.95, and has posted a year-to-date gain of approximately 3.7%, underperforming the broader S&P 500. Analyst consensus remains a Strong Buy, with an average 12-month price target of $11.44 — representing roughly 120% upside from current levels. However, the stock has a history of sharp post-earnings reactions: following the Q1 2026 report in May, shares dropped over 10% in a single day despite a narrow EPS beat, as the significant revenue miss and absence of a near-term clinical catalyst weighed on sentiment. The Q4 2025 report in March triggered an even steeper decline of nearly 13%. Key risks heading into this quarter include the possibility that the FHD-909 expansion decision is not disclosed alongside earnings and that collaboration revenue variability obscures underlying financial progress.

Forward Outlook and Key Factors to Monitor

Looking beyond the Q2 print, the most consequential development on Foghorn's horizon is the FHD-909 dose-expansion decision within the Eli Lilly collaboration. FHD-909 is a first-in-class oral SMARCA2 selective inhibitor being evaluated in non-small cell lung cancer (NSCLC) patients with SMARCA4 mutations — a population representing roughly 10% of NSCLC cases with significantly worse prognosis and limited treatment options. CEO Adrian Gottschalk stated at the Goldman Sachs Healthcare Conference in June 2026 that he expects the collaboration to have enough data from 10 to 20 NSCLC patients to assess single-agent activity during the summer.

Beyond FHD-909, Foghorn's proprietary pipeline is advancing on multiple fronts. The selective CBP degrader program (FHT-171) for ER-positive breast cancer is progressing toward IND (Investigational New Drug)-enabling studies later this year, with a potential IND filing in 2027. The selective EP300 degrader program, targeting multiple myeloma and diffuse large B-cell lymphoma, is undergoing formulation work for once-weekly subcutaneous administration. An undisclosed inflammation and immunology (I&I) asset is also tracking toward preclinical toxicity studies.

On the financial side, with $183.6 million in cash and equivalents as of March 31, 2026 — bolstered by a $50 million registered direct financing completed in January — Foghorn has runway into the first half of 2028. However, advancing multiple programs toward the clinic will require additional capital, and investors should monitor cash burn trends and any signals about future financing strategies. For a company where clinical data, not quarterly earnings, ultimately defines value, the Q2 report's greatest significance may lie in what management signals about the timing and nature of upcoming pipeline catalysts.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations